Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:47:48 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:SUPN - SUPERNUS PHARMACEUTICALS INC - https://www.supernus.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SUPN - Q1.015.00·55.000.151.65+2.284.6894.045,3988,37450.01  51.99  50.0157.65  29.1617:12:15Dec 0315 min RT 2¢

Recent Trades - Last 10 of 8374
Time ETExPriceChangeVolume
17:12:15Q51.652.2840
16:53:39Q51.652.281,970
16:53:39Q51.652.288,555
16:10:04Q51.652.281
16:10:04Q51.652.281
16:10:04Q51.652.281
16:04:33Q51.652.281
16:04:18Q51.652.281
16:04:16Q51.652.281
16:04:09Q51.652.281

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-03 16:05U:SUPNNews ReleaseSupernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
2025-11-21 16:06U:SUPNNews ReleaseSupernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
2025-11-12 16:05U:SUPNNews ReleaseSupernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
2025-11-04 16:01U:SUPNNews ReleaseSupernus Announces Third Quarter 2025 Financial Results
2025-10-21 17:00U:SUPNNews ReleaseSupernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
2025-09-17 16:30U:SUPNNews ReleaseBiogen Receives European Commission Approval for ZURZUVAE(TM) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
2025-08-27 16:15U:SUPNNews ReleaseSupernus Pharmaceuticals to Participate in September Investor Conferences
2025-07-31 08:44U:SUPNNews ReleaseSupernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
2025-07-28 08:25U:SUPNNews ReleaseSupernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
2025-07-22 16:30U:SUPNNews ReleaseSupernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
2025-06-16 07:00U:SUPNNews ReleaseSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
2025-05-29 08:31U:SUPNNews ReleaseJay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree(TM) Content Series with Supernus Pharmaceuticals
2025-05-28 16:06U:SUPNNews ReleaseSupernus Announces Paragraph IV ANDA Filings for Qelbree(TM)
2025-05-28 16:05U:SUPNNews ReleaseSupernus to Participate in the 2025 Jefferies Global Healthcare Conference
2025-05-20 08:30U:SUPNNews ReleaseBusy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being 'Ms. Represented' in First-of-its-Kind Campaign with Supernus Pharmaceuticals
2025-05-06 16:08U:SUPNNews ReleaseSupernus Announces First Quarter 2025 Financial Results
2025-04-23 17:14U:SUPNNews ReleaseSupernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
2025-03-04 16:31U:SUPNNews ReleaseSupernus to Participate in Two Upcoming Investor Conferences
2025-02-27 08:30U:SUPNNews ReleaseSupernus to Participate in the TD Cowen 45th Annual Health Care Conference
2025-02-25 16:02U:SUPNNews ReleaseSupernus Announces Fourth Quarter and Full Year 2024 Financial Results